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Interleukin-2 (IL-2) administered intravenously as a single
agent or together with lymphokine activated killer cells has
been shown to have activity against a variety of tumours
with the highest response rates recorded in patients with
renal cell carcinoma and melanoma (21-35%, Rosenberg et
al., 1989). The precise mechanism by which IL-2 causes
tumour regression is uncertain but it may involve the activa-
tion of cellular immune mechanisms. In vivo IL-2 stimulates
the proliferation of a variety of lymphoid cells including
activated T cells, natural killer cells, lymphokine activated
killer cells, B cells and macrophages (Gillis & Smith, 1977;
Henny et al., 1981; Grimm et al., 1982; Waldmann et al.,
1984; Malkovsky et al., 1987). IL-2 is a powerful regulator of
the immune system and although it is detectable in the serum
of healthy controls and cancer patients (Lissoni et al., 1990)
its main site of action is probably at a local level. Therefore,
a more physiological approach to the administration of IL-2
might be to deliver it locally to sites where potentially tumor-
icidal lymphocytes may be concentrated. Such loco-regional
therapy should also be associated with fewer systemic side
effects. Continuous intralymphatic infusions over a period of
days are not technically possible but a similar result could be
achieved by the intra-arterial route. Patients with tumours of
the head and neck were selected for this treatment approach
as the arterial supply to these tumours is frequently accessible
to cannulation. In addition these lesions are often easily
biopsied and provide a unique opportunity to study the
histopathological and immunohistochemical changes associ-
ated with the local delivery of varying concentations of IL-2.
We present the first stage of this programme which is a
phase I dose escalation study of intra-arterial IL-2 admini-
stered by continuous infusion over a maximum of 10 days to




Patients with recurrent or untreated, but incurable squamous
cell carcinoma of the head and neck were eligible for the
study. Patients had to satisfy the following criteria before
entry: performance status 0-1 (ECOG), WBC>4 x 109 per
litre, platelets> 100,000 x 109 per litre, HCT>30%, normal
serum bilirubin and creatinine and the principal blood supply
to the tumour had to be from a branch of the external
carotid artery. Patients were excluded if they had a signi-
ficant history ofcardiovascular disease, a contra-indication to
the use of pressor agents, a previous organ allograft, a
serious active infection, a requirement for corticosteroids or
had a concurrent second primary malignancy. Patients gave
fully informed, witnessed, written consent as laid down by
the Ethics Committee of the Royal Marsdan Hospital,
London.
A total of 15 patients fulfilled the entry criteria but two
refused treatment and one was unable to give fully informed
consent for psychological reasons. Thus, 12 patients (nine
male, three female) with a median age of 55 years (range
31-72) were treated with intra-arterial IL-2. Ten patients had
recurrent disease after radiotherapy and/or surgery and two
had previously untreated but incurable disease.
Administration
High-flow nylon (4.0 G) or vertebral (3.7 G; 4.7 G) catheters
(William Cook Europe Ltd) were inserted retrogradely under
general anaesthetic via an arteriotomy in the superficial tem-
poral artery in all but two cases. In these patients the
catheters were inserted directly into the maxillary and
superior thyroid arteries. The position of the catheter was
checked by angiography or by the instillation of fluorescein
(10% w/v) into the line. Heparin (50 iu in 50 ml normal
saline) was infused at 2.5 ml h' through the catheter for
24 h while patients recovered from the general anaesthetic.
Two out of the first three patients entered developed line
blockages/arterial thrombosis during the first 48 h of treat-
ment and therefore all subsequent patients were systemically
anti-coagulated with intravenous heparin. The dose was
altered daily according to the partial thromboplastin time.
IL-2 in 60 ml of 5% dextrose with 2.5% albumin (final
concentration) was administered daily over 24 h by con-
tinuous intra-arterial infusion via a syringe pump.
Study design
We intended to enter three patients at each dose level which
were as follows: level 1, 3 x 104 iu day; level 2, 3 x I05 iuday;
level 3, 3 x 106 iuday; level 4, 3 x 107 iu (Table I). The first
patient was treated for 5 days, patients 2-4 for 10 days with
a 2 day break after 5 days and subsequently it was planned that all patients should receive continuous treatment for 10
days. However, the two patients treated at the highest dose
level (3 x 107 iu day) required a 2 day break after 5 days of
treatment because of systemic toxicity.
The end point of the study was the development of
systemic toxicity typical of intravenous interleukin-2 at stan-
dard dose which for most continuous infusion regimens is
18 x I06iu m2day.
Table I Dose schedule
Level Dose iul24 h Schedule days n
1 3x 104 5 1
5-2-5 2
2 3 x105 5-2-5 1
10 3
3 3 x 106 10 3
4a 3 x 107 5-2-5 .2
aEquivalent iv treatment dose.
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Assessment oftoxicity and response
Patients were assessed daily for subjective toxicity (WHO
criteria) and for local complications. For those toxicities
where no WHO grade exists an arbitrary scale was used, side
effects were recorded as mild (grade 1), moderate (grade 2),
severe (grade 3) or life threatening (grade 4). Venepuncture
was performed daily to measure FBC, serum creatinine, urea
and electrolytes, clotting studies, liver function tests, gamma
GT, albumin and calcium. Chest X-ray, blood cultures and
MSUs were performed weekly. Pre- and post-treatment biop-
sies were obtained in 11 patients; one patient had a pre-
treatment biopsy only as she refused biopsy post-treatment.
Tumour response was defined according to standard
criteria: Complete response (CR) was defined as the disap-
pearance of all clinical, radiological and biochemical evidence
of disease for at least 1 month; partial response (PR) was
defined as a reduction in the product of two diameters of
measurable disease by at least 50% for at least 1 month
(Miller et al., 1981).
Results
Patients treated at dose levels 1-3 did not experience any
significant systemic side effecs (Tables II and III) and remain-
ed fully mobile and capable of self-care. However systemic
toxicity typical of iv IL-2 at standard dose was seen at the
highest dose level (level 4; 3 x I07 iu day). The two patients
treated at this dose experienced anorexia, nausea, fever,
fatigue, weight gain and transient abnormalities of liver func-
tion (grade 1). In addition, one of these patients became
hypoalbuminaemic and experienced episodes of hypotension
(grade 3) while the other complained of shortness of breath
(grade 2) and dry desquamation of his skin (grade 2).
The commonest toxicities encountered were local: tumour
pain, eight patients; facial oedema, eight patients; infection/
facial cellulitis, four patients. These side effects were not
dose-related and resolved during the week following cessation
of treatment. The four patients with signs of local cellulitis
were treated with antibiotics although none had a positive
blood culture. Two patients had haemorrhages from their
Table II Subjective toxicity. Worse WHO grade recorded at all dose
levels
WHO Grade
0 1 2 3 4
Fever 2 2 8 0 0
Wt loss 8 0 4 0 0
Oedema 9 1 2 0 0
CNS 6 5 1 0 0
Sore mouth 6 5 1 0 0
Nausea/Vomiting 6 5 1 0 0
Anorexia 7 3 1 1 0
Weight loss 9 0 3 0 0
SOB 8 3 1 0 0
Pruritus 9 2 1 0 0
Diarrhoea 8 4 0 0 0
Taste 10 2 0 0 0
Rigor 11 1 0 0 0
CNS = central neurological symptoms. SOB = shortness of breath.
Table III Objective toxicity. Worse WHO grade recorded at all dose
levels
WHO Grade
0 1 2 3 4
Anaemia 6 2 3 1 0
Hypotension 8 0 3 1 0
Infection 8 0 3 1 0
Liver 8 3 1 0 0
Proteinuria 8 3 1 0 0
Platelets + 11 1 0 0 0
tumours that may have been related to their anticoagulation.
Initially there were considerable problems maintaining the
patency of the arterial lines. The first three patients were not
systemically anticoagulated and two ofthese patients had line
failures within 48 h of catheter insertion due to arterial
thrombosis and the lines were consequently removed. One of
these patients was able to complete treatment after the
catheter was resited. There were no obvious local factors to
account for these failures and once subsequent patients were
systemically anticoagulated this problem did not recur.
Seven patients developed eight positive bacterial cultures at
the following sites: sputum, three cultures (Candida albi-
cans x two patients, B. haemolytic streptococcus); arterial
catheter tip, two cultures (Klebsiella pneumoniae, Staphyl-
ococcus epidermidis); wound, two cultures (Haemolytic strep-
tococcus, Staphylococcus epidermidis); blood, one culture
(Staphylococcus epidermidis).
Two patients who received the lowest dose of IL-2, 3 x 104
iv day had partial responses and no response were seen at
doses above this level.
Discussion
We have found that significant systemic side effects do not
occur with intra-arterial IL-2 at doses of 3 x 106 iu day and
below. At a dose of 3 x I07 iu day systemic toxicity is similar
to that seen with standard intravenous regimens. Local com-
plications were greater than expected particularly those of
cellulitis, facial oedema and arterial thrombosis. The cellulitis
and local oedema were not due to infection although we and
others have reported an increased risk of infection associated
with IL-2 therapy (Hartmann et al., 1989; Bock et al., 1990;
Hardy et al., 1990). Histological examination of post-treat-
ment biopsies did not reveal any specific explanation for this
complication (data not shown). Arterial thrombosis was a
major problem during the early part of the study until
patients were systemically anti-coagulated. There have been
previous reports of local thrombus associated with intra-
arterial IL-2 (Klasa & Silver, 1989; Eggermont et al., 1990;
Mavligit et al., 1990) and it has been suggested that this is
due to direct damage to the vascular endothelium by IL-2
activated lymphocytes (Damle et al., 1987), activation of the
intrinsic system of coagulation (Fleischmann et al., 1991) or
an increase in the coagulant properties of endothelium by
IL-2- induced cytokines such as IL-1 and tumour necrosis
factor (Cotran & Pober, 1989).
Phase II trials in patients with squamous cell carcinoma of
the head and neck utilising perilymphatic injections have
been performed but reported response rates vary widely,
from 0-8% (Selvaggi et al., 1990; de Mulder et al., 1989) to
65% (Cortesina et al., 1991). All these studies suggested that
systemic toxicity is absent when this approach is employed,
but at doses of 103 iu local swelling and pain occurred similar
to that observed in our patients (Cortesina et al., 1991). In
these studies bolus doses were given and thus the tumour
infiltrating lymphocytes were only intermittently exposed to
IL-2. It is possible that continuous exposure to IL-2 might
result in a greater anti-tumour effect.
Head and neck cancers are often easily accessible to biopsy
and therefore a programme of locally infused IL-2 presents a
unique opportunity to study the precise changes that take
place within tumours as a result of prolonged exposure to
both high and low local concentrations of IL-2. In addition,
intra-arterial IL-2 studies have important implications for
those groups who are studying targeted gene therapy. Unless
continuous intra-tumoral infusions of IL-2 cause tumour
regressions then it is unlikely that a strategy utilising IL-2
secreting tumour infiltrating lymphocytes will be of benefit.
We suggest that groups currently working on targeted gene
therapy study the effects of locally infused IL-2 before
embarking on any clinical trials.INTRA-ARTERIAL IL-2 IN HEAD AND NECK CANCER 407
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